Search for: "Matter of KB"
Results 241 - 241
of 241
Sorted by Relevance
|
Sort by Date
19 Jul 2022, 2:59 pm
In the following guest post, the authors revisit the question of whether or not securities class action lawsuits against development-stage biotech companies are likelier to survive a motion to dismiss compared to securities suits against other kinds of companies. [read post]
